| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | BMS-754807 | FIMM | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |